These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 30691084)
1. Evaluation of the Performance of 18F-Fluorothymidine Positron Emission Tomography/Computed Tomography (18F-FLT-PET/CT) in Metastatic Brain Lesions. Nikaki A; Papadopoulos V; Valotassiou V; Efthymiadou R; Angelidis G; Tsougos I; Prassopoulos V; Georgoulias P Diagnostics (Basel); 2019 Jan; 9(1):. PubMed ID: 30691084 [TBL] [Abstract][Full Text] [Related]
2. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer? Schaefferkoetter JD; Carlson ER; Heidel RE J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746 [TBL] [Abstract][Full Text] [Related]
3. 18F-FDG or 3'-deoxy-3'-18F-fluorothymidine to detect transformation of follicular lymphoma. Wondergem MJ; Rizvi SN; Jauw Y; Hoekstra OS; Hoetjes N; van de Ven PM; Boellaard R; Chamuleau ME; Cillessen SA; Regelink JC; Zweegman S; Zijlstra JM J Nucl Med; 2015 Feb; 56(2):216-21. PubMed ID: 25593118 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study. Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837 [TBL] [Abstract][Full Text] [Related]
5. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma. Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650 [TBL] [Abstract][Full Text] [Related]
6. 3'-Deoxy-3'-(18F) Fluorothymidine Positron Emission Tomography/Computed Tomography in Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy: A Pilot Study. Lewis S; Chan M; Weiss J; Raziee H; Driscoll B; Bezjak A; Sun A; Lok B; Vines D; Cho J; Bissonnette JP; Raman S; Hope A; Giuliani M Adv Radiat Oncol; 2022; 7(6):101037. PubMed ID: 36420186 [TBL] [Abstract][Full Text] [Related]
7. 18F-FLT Positron Emission Tomography/Computed Tomography Imaging in Pancreatic Cancer: Determination of Tumor Proliferative Activity and Comparison with Glycolytic Activity as Measured by 18F-FDG Positron Emission Tomography/Computed Tomography Imaging. Debebe SA; Goryawala M; Adjouadi M; Mcgoron AJ; Güleç SA Mol Imaging Radionucl Ther; 2016 Feb; 25(1):32-8. PubMed ID: 27299286 [TBL] [Abstract][Full Text] [Related]
8. FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumours. Nakajo M; Jinguji M; Fukukura Y; Kajiya Y; Tani A; Nakajo M; Nakabeppu Y; Arimura H; Nishio Y; Nakamura F; Yoshiura T Eur Radiol; 2015 Dec; 25(12):3696-705. PubMed ID: 25925356 [TBL] [Abstract][Full Text] [Related]
9. Assessment of grading in newly-diagnosed glioma using 18F-fluorothymidine PET/CT. Ferdová E; Ferda J; Baxa J; Tupý R; Mraček J; Topolčan O; Hes O Anticancer Res; 2015 Feb; 35(2):955-9. PubMed ID: 25667480 [TBL] [Abstract][Full Text] [Related]
10. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging. Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223 [TBL] [Abstract][Full Text] [Related]
11. Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging. Wang FL; Tan YY; Gu XM; Li TR; Lu GM; Liu G; Huo TL Chin Med J (Engl); 2016 Dec; 129(24):2926-2935. PubMed ID: 27958224 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions. Beauregard JM; Giraudet AL; Aide N; Hofman MS; Blum R; Drummond E; Roselt P; Hicks RJ Nucl Med Commun; 2013 Jun; 34(6):521-6. PubMed ID: 23542911 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of interim fluorodeoxyglucose and fluorothymidine PET/CT in diffuse large B-cell lymphoma. Wang R; Xu B; Liu C; Guan Z; Zhang J; Li F; Sun L; Zhu H Br J Radiol; 2018 Nov; 91(1091):20180240. PubMed ID: 30004787 [TBL] [Abstract][Full Text] [Related]
14. An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3'-deoxy-3'[(18)F]-Fluorothymidine Positron Emission Tomography Kairemo K; Ravizzini GC; Macapinlac HA; Subbiah V Diagnostics (Basel); 2017 Apr; 7(2):. PubMed ID: 28375169 [TBL] [Abstract][Full Text] [Related]
15. Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial. Zanoni L; Broccoli A; Lambertini A; Pellegrini C; Stefoni V; Lodi F; Fonti C; Nanni C; Zinzani PL; Fanti S Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1661-1671. PubMed ID: 31102000 [TBL] [Abstract][Full Text] [Related]
16. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer. Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733 [TBL] [Abstract][Full Text] [Related]